Belite Bio (NASDAQ: BLTE) will host a webcast on May 20, 2026 at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a business update. Investors can access the live webcast and a 90-day replay via the company’s investor relations website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – BLTE
-2.33%
-2.33%Session close to close
In the May 14 session, BLTE declined 2.33%, reflecting a moderate negative market reaction.
This announcement schedules a Q1 2026 webcast, continuing Belite Bio’s pattern of pairing financial ...
Analysis
This announcement schedules a Q1 2026 webcast, continuing Belite Bio’s pattern of pairing financial reporting with broader corporate and clinical updates. Historically, earnings-tagged releases have highlighted tinlarebant trial progress, significant cash and investment balances, and sizable net losses as R&D and G&A spending increased. Investors may watch for updates on NDA progress, cash runway, and any changes in operating expenses or financing activity discussed during the call, alongside DRAGON and PHOENIX program status.
Key Figures
Lesion growth reduction:35.7%Public offering:$402 millionCash balance:$352.9M+5 more
8 metrics
Lesion growth reduction35.7%Phase 3 DRAGON topline vs placebo in Stargardt disease type 1
Public offering$402 millionCompleted public offering noted in 2025 results update
Cash balance$352.9MCash entering 2026 per preliminary 2025 results
Investments balance$419.7MInvestments entering 2026 per preliminary 2025 results
GAAP net loss 2025$77.6MFull-year 2025 GAAP net loss
DRAGON II enrollment72 subjectsDRAGON II targeted enrollment as of Feb 27, 2026
PHOENIX enrollment530 subjectsPHOENIX trial enrollment completion noted in 2025 update
Q2 2025 net loss$16.3 millionNet loss for second quarter 2025
Q1 results, DRAGON/PHOENIX progress, new financing, and higher operating costs.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Earnings-related news often mixes strong clinical/financing updates with widening net losses, producing a blend of up and down reactions, with slight bias toward alignment.
Recent Company History
Over the last year, Belite Bio’s earnings-tagged news combined financial updates with major clinical milestones for tinlarebant. Prior releases highlighted Phase 3 DRAGON efficacy, multiple financings, growing cash and investment balances, and net losses widening as R&D and G&A spending increased. Price reactions to these five earnings events were mixed but leaned toward alignment in three cases. Today’s Q1 2026 webcast announcement continues the pattern of pairing financial reporting with broader corporate updates.
Key Terms
new drug application, breakthrough therapy designation, priority review, conditional marketing authorization, +4 more
8 terms
new drug applicationregulatory
"has initiated a rolling submission of a New Drug Application to the FDA"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
breakthrough therapy designationregulatory
"The FDA previously granted Breakthrough Therapy Designation and approved the rolling submission."
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
priority reviewregulatory
"China NMPA agreed to accept an NDA with priority review"
Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.
conditional marketing authorizationregulatory
"UK MHRA agreed to accept a Conditional Marketing Authorization application for Tinlarebant"
A conditional marketing authorization is a limited, temporary approval from a drug regulator that lets a medicine or vaccine be sold based on earlier or smaller amounts of safety and effectiveness data than normally required, usually because the treatment addresses a serious unmet need. It matters to investors because it can allow a company to start generating revenue sooner—like a provisional driver’s license—while carrying higher regulatory and clinical risk if follow‑up studies fail or additional data are required.
registered direct offeringfinancial
"The company closed a $15M registered direct offering and a $125M private placement"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
private placementfinancial
"closed a $15M registered direct offering and a $125M private placement"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
rule 10b5-1 trading planregulatory
"The sales were made under a Rule 10b5-1 trading plan adopted on December 10, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
form 20-fregulatory
"annual report on Form 20-F, containing audited consolidated financial statements"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Wednesday, May 20, 2026, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2026.
Webcast Link Instructions You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.
Media and Investor Relations Contact: Jennifer Wu ir@belitebio.com
When is Belite Bio (BLTE) Q1 2026 financial results webcast?
Belite Bio will hold its Q1 2026 webcast on Wednesday, May 20, 2026 at 4:30 p.m. Eastern Time. According to the company, the event will cover first quarter financial results and a broader business update.
How can investors access the Belite Bio (BLTE) Q1 2026 webcast?
Investors can access the Belite Bio webcast through a provided webcast link and the “Presentations & Events” section of its investor relations website. According to the company, the webcast will be available live and as a replay.
Will a replay be available for the Belite Bio (BLTE) May 20, 2026 webcast?
Yes, a replay of Belite Bio’s May 20, 2026 webcast will be available for about 90 days. According to the company, the replay can be accessed via its investor relations website after the live event.
What will Belite Bio (BLTE) discuss during the May 20, 2026 webcast?
Belite Bio plans to discuss financial results for the first quarter ended March 31, 2026 and provide a business update. According to the company, the webcast targets investors following its clinical-stage biopharmaceutical activities.
What time does the Belite Bio (BLTE) Q1 2026 webcast start in Pacific Time?
The Belite Bio Q1 2026 webcast begins at 1:30 p.m. Pacific Time on May 20, 2026. According to the company, this corresponds to 4:30 p.m. Eastern Time for U.S.-based investors.
